NEUROPATHIX, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2022-03-25: Form 8-K; Period of report 2022-03-21; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; Details 1.01.
- 2021-09-28: Form 8-K; Period of report 2021-09-28; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2021-03-17: Form 8-K; Period of report 2021-03-12; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2021-02-23: Form 8-K; Period of report 2021-02-17; Description 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2022-03-25 | 8-K | 2022-03-21 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 On March 21, 2022, Neuropathix, Inc. (the "Company") issued three (3) convertible notes on identical terms to three private investors having an aggregate face value of $150,000 (the "Convertible Notes"). 2.03 The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. 3.02 The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. | nptx032422form8k.htm |
| 2021-09-28 | 8-K | 2021-09-28 | 7.01 Regulation FD Disclosure | 7.01 On September 28, 2021, Neuropathix, Inc., a Delaware corporation (the “Company”), issued a press release announcing that its subsidiary Kannalife Sciences, Inc. was awarded a $2.97 million Phase 2 STTR Study Grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). | nptx092721form8k.htm |
| 2021-03-17 | 8-K | 2021-03-12 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 12, 2021, Neuropathix, Inc., a Delaware corporation (the “Company”), executed that certain second amendment to the Company’s 2019 Equity Incentive Plan to (i) replace all references to “Kannalife, Inc.,” the Company’s former name, to “Neuropathix, Inc.,” and (ii) increase the number of shares of Company common stock authorized for issuance thereunder from 11,250,000 to 20,000,000 shares (the “Plan Amendment”). | nptx031621form8k.htm |
| 2021-02-23 | 8-K | 2021-02-17 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 3.02 The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02. | nptx021821form8k.htm |
| 2020-12-21 | 8-K | 2020-12-17 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 3.02 The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02. 7.01 On December 21, 2020, the Company issued a press release regarding the Transaction. | nptx122120form8k.htm |
| 2020-11-19 | 8-K | 2020-11-17 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 7.01 On November 19, 2020, the Company issued a press release regarding the Binding Letter of Intent. | nptx111920form8k.htm |
| 2020-11-06 | 8-K | 2020-11-04 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On November 4, 2020, Kannalife, Inc., a Delaware corporation (the “Company”), filed a Certificate of Amendment to the Company’s Certificate of Incorporation (the “Certificate of Amendment”) to effect a change of the Company’s name to Neuropathix, Inc. The Certificate of Amendment became effective upon filing with the Secretary of State of the State of Delaware. | klfe110620form8k.htm |
| 2020-09-22 | 8-K | 2020-09-18 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | klfe092120form8k.htm |
| 2020-06-29 | 8-K | 2020-06-23 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 2.03 The disclosure under Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 2.03 by reference. 3.02 The disclosure under Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 3.02 by reference. | klfe062920form8k.htm |
| 2020-06-11 | 8-K | 2020-06-08 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 2.03 The disclosure under Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 2.03 by reference. 3.02 The disclosure under Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 3.02 by reference. | klfe061120form8k.htm |
| 2020-03-18 | 8-K | 2020-03-12 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 2.03 The disclosure under Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 2.03 by reference. 3.02 The disclosure under Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 3.02 by reference. | klfe031820form8k.htm |
| 2020-01-28 | 8-K | 2020-01-28 | 7.01 Regulation FD Disclosure | 7.01 On January 28, 2020, Kannalife, Inc. (the “Company”) issued a letter (the “Stockholder Letter”) to its stockholders regarding the Company’s recent initiatives and corporate updates (the “Updates”). | klfe012720form8k.htm |
| 2018-10-05 | 8-K | 2018-10-04 | 4.01 Changes in Registrant's Certifying Accountant | f8k100418_8k.htm | |
| 2018-10-02 | 8-K/A | 2018-07-25 | 1.01 Entry into a Material Definitive Agreement | f8ka092818_8kz.htm | |
| 2018-07-31 | 8-K | 2018-07-25 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.02 Unregistered Sales of Equity Securities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | f8k073118_8k.htm | |
| 2018-07-30 | 8-K | 2018-07-24 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | f8k073018_8k.htm | |
| 2018-05-25 | 8-K/A | 2018-05-01 | 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders | f8ka052418_8kz.htm | |
| 2018-05-04 | 8-K | 2018-05-01 | 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders | f8k050418_8k.htm | |
| 2018-04-25 | 8-K | 2018-04-23 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On April 23, 2018, TYG Solution Corp.’s (the “Company”) Board of Directors approved the engagement of Accell Audit and Compliance, P.A., 4806 West Gandy Boulevard, Tampa, FL 33611, Phone: (813) 440-6380 (“Accell”) as its independent registered public accounting firm for the fiscal years ended December 31, 2017 and December 31, 2016. | f8k042518_8k.htm |
| 2018-04-18 | 8-K | 2018-04-12 | 4.01 Changes in Registrant's Certifying Accountant; 8.01 Other Events | 4.01 On April 12, 2018, TYG Solutions, Inc. (the “Company”) received a letter from PLS CPA, A Professional Corp. (“PLS CPA”), stating that PLS CPA had resigned as the Company’s independent registered public accounting firm. 8.01 Annual Report for the Year ended December 31, 2017. | f8k041118_8k.htm |
| 2018-03-09 | 8-K | 2018-03-05 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On March 5, 2018, TYG Solutions, Inc. (the “Registrant” or the “Company”) received notification from the Securities and Exchange Commission (the “Commission”) that its independent registered public accounting firm, Weinberg & Baer, LLC (“Weinberg”), had been suspended from appearing or practicing before the Commission. | f8k030618_8k.htm |
| 2017-06-21 | 8-K | 2017-06-20 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. | f8k062017_8k.htm |